Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Prophylactic Mastectomy with Primary Expander Implants


The timing of riskreducing mastectomy should be meticuously discussed with each patient as we know the riskincreases from the age of 25 years. For the majority this can be adequately performed around 30 years of age.


  • Known mutations of BRCA 1.
  • For mutation of BRCA 2 or hereditary breast cancer without a known gene mutation (the indication is not as clear as for BRCA1 mutation, because the prognosis is as good as in sporadic breast cancer).


  • To avoid development of breast cancer.
  • In some cases, the goal may be to reduce the number of follow-up examinations and possible complications associated with these.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018